Scientific Publications

XenoPort Publications on XP19986

2007 Digestive Disease Week Poster Presentation: R-baclofen Prodrug XP19986 Decreases Reflux and is Well Tolerated in GERD Patients [PDF - 759 Kb]
2006 American College of Gastroenterology Poster Presentation: XP19986 Decreases Reflux and is Well Tolerated in GERD Patients [PDF - 415 Kb]

XenoPort Publications on XP13512

2006 APSS Meeting Presentation: XP13512 Improves Symptoms and Sleep Disturbance in RLS Patients: Results of a 2-Week, Randomized, Double-Blind, Placebo-Controlled Cross-Over Polysomnography Trial [PDF - 212 Kb]
2006 APS Meeting Presentation: Gabapentin Exposure and Pain Reduction in Patients with Postherpetic Neuralgia: Analysis of a Phase 2a Randomized, Double-Blind, Placebo-controlled Study of Neurontin® and XP13512 [PDF - 205 Kb ]
2006 AAN Meeting Presentation: XP13512 is Well Tolerated and Effective in Treating Moderate to Severe Restless Legs Syndrome in a 2-week Randomized, Double-Blind, Placebo-Controlled, Exploratory Trial [PDF - 251 Kb ]
A Phase 1 Randomized, Cross Over, Single Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of XP13512 Sustained Release Tablets Vs. Neurontin® In Healthy Adult Subjects [PDF - 101 Kb ]
Single- And Multi-Dose Phase 1 Studies Of XP13512, A Transported Prodrug Of Gabapentin, Demonstrate Safety, Tolerability, And Dose-Proportional Gabapentin Pharmacokinetics [PDF - 122 Kb ]

An Overview of Treatments for Restless Legs Syndrome

Fulda, S., and T. C. Wetter. "Emerging Drugs for Restless Legs Syndrome." Expert Opinion on Emerging Drugs 10, no. 3 (2005): 537-52.

The Use of Baclofen for the Treatment of GERD

Vela, M. F., R. Tutuian, P. O. Katz, and D. O. Castell. "Baclofen Decreases Acid and Non-Acid Post-Prandial Gastro-Oesophageal Reflux Measured by Combined Multichannel Intraluminal Impedance and Ph." Alimentary Pharmacology & Therapeutics 17, no. 2 (2003): 243-51.

Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease

This icon indicates a link to an external site.

You need the free Acrobat Reader to view documents on this page.

"Our goal is to improve patient treatment by creating novel, patentable compounds with greater efficacy or reduced side effects compared to current therapies, due to improved pharmacokinetic properties. Our unique understanding of the active transport of nutrients into the body via transporter proteins has enabled us to take existing drugs and chemically modify them to enable recognition and transport by the transporter protein. We refer to these new chemical entities as Transported Prodrugs."

—Ken Cundy, Senior Vice President of Preclinical Development